[Home]
[Full version]
Stem cells used to create critical brain barrier in lab
Dec 20 ,Medicine & Health
Using neural stem cells derived from the fetal brains of rats, a team of Wisconsin scientists has devised a rudimentary blood-brain barrier in the lab.
Writing this week (Dec. 19) in the online editions of the Journal of Neurochemistry, a group led by University of Wisconsin-Madison professor of chemical and biological engineering Eric V. Shusta describes an experiment in which nascent rat neural stem cells were used to prod blood vessel cells to assume properties of the blood-brain barrier.
The blood-brain barrier is an anatomical feature in humans and other animals that protects the brain from chemicals and other harmful agents, but also limits the ability of clinicians to administer helpful drugs. It is a feature that can succumb to diseases such as Alzheimer's or acute conditions such as stroke, which can leave the brain vulnerable.
The blood-brain barrier is a critically important structure, Shusta says. Not only does it physically block the movement of substances between blood and brain, but it also possesses active properties that enable cells to pump unwanted molecules from cells back into the bloodstream. What's more, it has a metabolic function that can alter the chemical properties of the molecules that do get through to the brain.
"It dictates traffic in and out of the brain," Shusta explains.
Demonstrating that developing brain cells can release factors that may coax small blood vessels to exhibit the properties of the blood-brain barrier is important for a number of reasons. First, it forms a basis for understanding the mechanism that provides critical protection for the brain. Second, it may lead to insights regarding ways to overcome a barrier that frustrates neuroscientists, drug companies and clinicians who would like to sneak drugs past it to treat disease.
"What we have shown is that these neural stem cells have the ability to stimulate adult blood vessel endothelial cells to display enhanced blood-brain barrier properties," Shusta says. "This may lead to new in-vitro models of the blood-brain barrier."
That in turn may help researchers devise new therapies to treat brain disease and to form a clear understanding of how the barrier forms during the course of development.
"One of the big questions of (brain) development is how does the blood-brain barrier form and when does it form," says Shusta. "That's poorly understood."
The Wisconsin team, which includes UW-Madison School of Medicine and Public Health professor and stem cell authority Clive Svendsen, used brain stem cells grown as "neurospheres" to coax brain endothelial cells — flat cells that line blood vessels — to form a tighter, more dense barrier to small molecules that would otherwise diffuse through the blood vessel cells.
What is curious, according to Shusta and Svendsen, is that during development, brain endothelial cells form an enhanced barrier in the complete absence of astrocytes, a mature type of cell that serves as the two-by-four of the brain, but which do not appear in great numbers until birth. Astrocytes provide both structural support and are critical to the maintenance of the adult blood-brain barrier.
"One of the things we found is that the neural stem cells had a significant effect on the development of blood-brain barrier properties in the absence of astrocytes," Svendsen says. "It is possible these cells take on the role of astrocytes in early development and may be very important for establishing the initial barrier prior to the astrocytes taking over and completing the barrier."
The new work was accomplished by culturing endothelial cells in concert with the neurospheres. Somehow, the neurospheres prompted the endothelial cells to form tighter, denser cell-to-cell junctions, enhancing their ability to form a barrier and exclude small chemical molecules from passing through, a hallmark of the blood-brain barrier.
Using neural stem cells, Svendsen argues, provides a new way to assess how the barrier forms in early development, insight that might provide clues about how to mend the barrier when it is broken through disease or events such as stroke.
"Could neural progenitor cells or stem cells have a role in forming the blood-brain barrier after damage or disease? The answer seems to be yes," says Svendsen.
The team will next try to produce similar results using human endothelial cells and neural stem cells. "That would be very exciting," Svendsen acknowledges. "We don't have a good model for a human blood-brain barrier."
Development of a human model, presumably, would be of enormous interest to researchers and pharmaceutical companies as many promising drugs are composed of molecules too big to pass through the human barrier and thus cannot be used in the clinic.
Source: University of Wisconsin-Madison
Related stories:
Brain cells called astrocytes undergo reorganization and may engulf attacking T cells
When virally infected cells in the brain called astrocytes come in contact with anti-viral T cells of the immune system, they undergo a unique series of changes that dramatically reorganize their shape and function, according to researchers at the Board of Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center. Intriguingly, the new data indicate that astrocytes may defend themselves from attacking T cells by engulfing (gobbling up) the aggressors.
Chemical liberated by leaky gut may allow HIV to infect the brain
In up to 20 percent of people infected with HIV, the virus manages to escape from the bloodstream and cross into the brain, resulting in HIV-associated dementia and other cognitive disorders. Now, scientists at the Albert Einstein College of Medicine of Yeshiva University have found strong evidence that a component of the cell walls of intestinal bacteria—a chemical present in high levels in the blood of HIV-infected people—helps HIV to penetrate the usually-impregnable blood brain barrier (BBB). The findings, published in the August issue of the
Journal of Virology, could lead to strategies for preventing HIV from entering the brain and causing serious complications.
Cancer drug shows promise against graft vs. host disease
A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication for people who have had bone marrow transplants.
Ionophore reverses Alzheimer's within days in mouse models
Scientists report a remarkable improvement in Alzheimer's transgenic mice following treatment with a new drug. The study, published by Cell Press in the July 10th issue of the journal
Neuron, provides the first demonstration that an ionophore, a compound that transports metal ions across cell membranes, can elicit rapid and pronounced improvement in neuropathology and cognitive function in mouse models of Alzheimer's Disease (AD).
Researchers clear up Alzheimer's plaques in mice
Blocking a common immune system response cleared up plaques associated with Alzheimer’s Disease and enabled treated mice to recover some lost memory, Yale University researchers report Friday in the journal
Nature Medicine.
Appealing the death sentence for brain cells
A new drug candidate discovered by Tel Aviv University researcher Prof. Illana Gozes may lead to an effective treatment against the debilitative Alzheimer's disease. This compound could also treat a number of diseases where patients suffer from cognitive deficits, such as schizophrenia and Parkinson's, by limiting damage to the brain.
How buckyballs hurt cells
A new study into the potential health hazards of the revolutionary nano-sized particles known as ‘buckyballs’ predicts that the molecules are easily absorbed into animal cells, providing a possible explanation for how the molecules could be toxic to humans and other organisms.
Antibodies in the brain
Each of us carries an unbelievable multitude of antibodies, allowing us to survive the daily battle against pathogens. However, sometimes these antibodies go haywire and attack structures of their own body, for example nerve cells in patients with multiple sclerosis. The origin of these antibodies remained long unknown.
[Home]
[Full version]